StockData
Altimmune, Inc. logo

Altimmune, Inc. (ALT) stock

ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30
$1.39−0.14 (-9.15%)

Close on Nov 18, 2026Market cap $270.38MP/E –Yield –

Altimmune shares outstanding

Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.

Altimmune's shares outstanding was 185M at Jun 30, 2026. For fiscal 2025 it was 88M, up 24.1% from the year before. Over ten years it grew 81.4% a year on average. The highest annual figure on record is 88M in fiscal 2025.

Annual shares outstanding

PeriodPeriod endValueChange
FY2025Dec 31, 202588M+24.1%
FY2024Dec 31, 202471M+33.3%
FY2023Dec 31, 202353M+13.5%
FY2022Dec 31, 202247M+13.7%
FY2021Dec 31, 202141M+61.0%
FY2020Dec 31, 202026M+95.3%
FY2019Dec 31, 201913M+368.3%
FY2018Dec 31, 20183M+548.9%
FY2017Dec 31, 20170M+87.5%
FY2016Dec 31, 20160M+0.8%
FY2015Dec 31, 20150M+11.2%
FY2014Dec 31, 20140M+13.6%
FY2013Dec 31, 20130M+4.8%
FY2012Dec 31, 20120M+2.1%
FY2011Dec 31, 20110M+46.5%
FY2010Dec 31, 20100M–

Quarterly shares outstanding

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026185M+127.6%
Q1 FY2026Mar 31, 2026124M+64.7%
Q4 FY2025Dec 31, 2025106M+48.6%
Q3 FY2025Sep 30, 202589M+25.8%
Q2 FY2025Jun 30, 202581M+14.9%
Q1 FY2025Mar 31, 202576M+6.7%
Q4 FY2024Dec 31, 202471M+21.8%
Q3 FY2024Sep 30, 202471M+32.5%
Q2 FY2024Jun 30, 202471M+39.9%
Q1 FY2024Mar 31, 202471M+41.2%
Q4 FY2023Dec 31, 202358M+16.9%
Q3 FY2023Sep 30, 202354M+8.8%
Q2 FY2023Jun 30, 202351M+6.7%
Q1 FY2023Mar 31, 202350M+14.0%
Q4 FY2022Dec 31, 202250M+17.5%
Q3 FY2022Sep 30, 202249M+19.1%
Q2 FY2022Jun 30, 202248M+14.9%
Q1 FY2022Mar 31, 202244M+13.0%
Q4 FY2021Dec 31, 202143M+17.1%
Q3 FY2021Sep 30, 202141M+25.1%
Q2 FY2021Jun 30, 202141M+131.2%
Q1 FY2021Mar 31, 202139M+157.5%
Q4 FY2020Dec 31, 202036M+141.6%
Q3 FY2020Sep 30, 202033M+123.8%
Q2 FY2020Jun 30, 202018M+36.3%
Q1 FY2020Mar 31, 202015M+59.2%
Q4 FY2019Dec 31, 201915M+1039.4%
Q3 FY2019Sep 30, 201915M+1444.8%
Q2 FY2019Jun 30, 201913M+1840.4%
Q1 FY2019Mar 31, 20199M+1570.9%
Q3 FY2018Sep 30, 20181M+155.3%
Q2 FY2018Jun 30, 20181M+134.2%
Q1 FY2018Mar 31, 20181M+193.4%
Q4 FY2017Dec 31, 20171M+146.5%
Q3 FY2017Sep 30, 20171M+124.7%
Q2 FY2017Jun 30, 20170M–
Q1 FY2017Mar 31, 20170M–
Q4 FY2016Dec 31, 20160M–
Q3 FY2016Sep 30, 20160M–

More Altimmune figures

See a number that looks wrong?